Patents by Inventor Changlin Dou
Changlin Dou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250121082Abstract: An antibody or an antigen-binding fragment thereof that binds to CD228, and an antibody-drug conjugate containing the antibody or antigen-binding fragment thereof. The antibody or antigen-binding fragment thereof has a high affinity to a CD228 protein and an ability to mediate ADCC. The antibody-drug conjugate exhibits an inhibitory effect on various tumors. A nucleic acid encoding the antibody or antigen-binding fragment thereof; a cell containing the nucleic acid; a pharmaceutical composition containing the antibody or antigen-binding fragment thereof, the nucleic acid, the cell or the antibody-drug conjugate; and a kit. The use of the antibody or antigen-binding fragment thereof, the nucleic acid, the antibody-drug conjugate or the pharmaceutical composition in the prevention, treatment, detection or diagnosis of diseases related to CD228.Type: ApplicationFiled: May 25, 2023Publication date: April 17, 2025Inventors: Deyong SONG, Jing HAN, Hong LIU, Nan SHEN, Jie JIAO, Qiaoping WANG, Jianxia FENG, Min LI, Mengqi ZONG, Ying LI, Changlin DOU
-
Publication number: 20240342283Abstract: An ROR1 CAR or ROR1/CD19 Dual CAR for the treatment of tumors. The T cells expressing ROR1 CAR or ROR1/CD19 Dual CAR can be stimulated by ROR1-positive or ROR1/CD19-positive cells, and have cytotoxicity against ROR1-positive or ROR1/CD19-positive cells.Type: ApplicationFiled: August 15, 2022Publication date: October 17, 2024Inventors: Mengqi Zong, Jie Jiao, Jianxia Feng, Michael Harris, Xin Kai, Li Zhou, Ninghai Wang, Liangjun Wei, Hao Chen, Xian Wen, Changlin Dou, Chuangchuang Dong
-
Patent number: 10696973Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.Type: GrantFiled: March 27, 2018Date of Patent: June 30, 2020Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Gang Chen, Changlin Dou, James P. Fandl
-
Publication number: 20180216118Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked, Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.Type: ApplicationFiled: March 27, 2018Publication date: August 2, 2018Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Gang Chen, Changlin Dou, James P. Fandl
-
Patent number: 9944934Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.Type: GrantFiled: April 13, 2016Date of Patent: April 17, 2018Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Gang Chen, Changlin Dou, James P. Fandl
-
Patent number: 9469856Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.Type: GrantFiled: February 18, 2014Date of Patent: October 18, 2016Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Changlin Dou, Gang Chen, James P. Fandl
-
Publication number: 20160222094Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.Type: ApplicationFiled: April 13, 2016Publication date: August 4, 2016Inventors: Gang Chen, Changlin Dou, James P. Fandl
-
Publication number: 20140315249Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.Type: ApplicationFiled: February 18, 2014Publication date: October 23, 2014Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Changlin DOU, Gang CHEN, James P. FANDL
-
Patent number: 8673589Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.Type: GrantFiled: November 25, 2008Date of Patent: March 18, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Gang Chen, Changlin Dou, James P. Fandl
-
Publication number: 20090162901Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.Type: ApplicationFiled: November 25, 2008Publication date: June 25, 2009Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Gang Chen, Changlin Dou, James P. Fandl
-
Patent number: 7514545Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells. Expression of a nucleotide sequence of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When the cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale production of a desired product in eukaryotic cells.Type: GrantFiled: January 13, 2006Date of Patent: April 7, 2009Assignee: Regeneron Pharmaceuticals, Inc.Inventors: James P. Fandl, Changlin Dou
-
Patent number: 7455988Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells. Expression of a nucleotide sequence of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a legends-binding domain. When the cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale production of a desired product in eukaryotic cells.Type: GrantFiled: May 28, 2003Date of Patent: November 25, 2008Assignee: Regeneron Pharmaceuticals, Inc.Inventors: James P. Fandl, Changlin Dou